Sinogen Pharmaceutical was listed on the "Investorscn.com - 2023 China Value Enterprise List" and was once again awarded the "Future Unicorn" Innovation Enterprise in Guangzhou City

Recently, Investorscn.com released the “2023 China Value Enterprise List”, and Sinogen Pharmaceutical was listed on the "Top 100 Most Valuable Investment Enterprises in 2023". With its innovative drug research and development capabilities and outstanding achievements, Sinogen Pharmaceutical was once again successfully selected for the 2023 Guangzhou "Future Unicorn" Innovation Enterprise List.

About the "Investorscn.com - 2023 China Value Enterprise List"

The "Investorscn.com - 2023 China Value Enterprise List" is divided into three main parts, including "the most valuable investment enterprises in 2023", "the most investor focused listed companies in 2023", and "innovative enterprises in 2023". Based on an objective and fair attitude, the Investor Research Institute, combined with the Investor Network WFin database from dimensions such as growth, innovation, financing, patents, activity, and influence, finally selected innovative enterprises that meet the above criteria after several months, and jointly formed the "Investorscn.com - 2023 China Value Enterprise List".

About the Guangzhou "Future Unicorn" Innovation Enterprise List

The Guangzhou “Unicorn” Innovation Enterprise List is an authoritative list sponsored by the Guangzhou Science and Technology Innovation Enterprise Association, guided by the Guangzhou Municipal Bureau of Science and Technology. The selection process, including enterprise application and expert evaluation, aims to explore innovative enterprises with strong innovation, fast growth rate, and great development potential in Guangzhou, cultivate future leading innovative enterprises, and play a leading and demonstrative role in enterprise innovation. It is an important indicator for the development of Guangzhou's new economy. Among them, the "Future Unicorn" Innovation Enterprise List aims to explore innovative enterprises with the potential to become "Unicorn", targeting enterprises that have obtained institutional equity investments and market valuations between 100 million to 1 billion US dollars.

About Sinogen Pharmaceutical

Guangzhou Sinogen Pharmaceutical is a biopharmaceutical company dedicated to the development and production of innovative biological anti-tumor drugs to meet the demand of the global malignant tumor treatment market. Since its establishment in 2016, under the leadership of Dr. Allan Zijian Zhao and three other high-level experts, and through the joint efforts of dozens of scientific researchers, the company has gradually established the world's first rapid broad-spectrum oncolytic bacteria technology platform, and completed the core product of the oncolytic bacteria SalMet-Vec® pre-clinical research, CMC production process development, and construction of large-scale production facilities that comply with GMP standards. The core product SalMet-Vec® has obtained the IND approval from the US FDA, Taiwan TFDA and Mainland China NMPA, and is conducting an global multi-center phase I/IIa clinical trial for multiple malignant solid tumors in the US, Taiwan, and Mainland China.